Most immunotherapies try to build new immunity. ITCs™ redirect the immunity patients already have.
Solid tumors don't look foreign. The immune system can be released, unbraked, or engineered, but it still can't reliably find and kill the target.
Checkpoint inhibitors release the brakes. ADCs deliver drugs. CAR-T engineers immunity from scratch. All three are often anchored to a defined tumor marker, and clinical responses remain limited, with only up to ~40–50% of patients responding in many settings.
ITCs are modular recombinant proteins built on the same architecture regulators already understand and patients already tolerate. Unlike ADCs, we do not deliver a drug. We deliver a tag.
Selective. Localized. Non-immunosuppressive.
A modular antibody scaffold docks the surface marker. ORION™ uses HER2, the most studied target in oncology.
The conjugate carries a pathogen-derived signal peptide tag (BCG, CMV, or others). The tag was previously successfully tested in humans in earlier clinical programs.
Pathogen-primed CD8 memory T-cells recognize the cell as infected and clear it. Polyclonal. Picomolar sensitivity.
Works across diverse immune profiles.
Recruits multiple T-cell populations, not just one.
Gets to where T-cell immune signaling actually happens.
Works even when standard pathways are blocked.
Not new immunity. Not engineered immunity. Memory immunity.
BCG. CMV. EBV. The training is already done.
Scaffold and signal peptide both have human clinical history.
Swap the targeting arm, the tag, or the cell type. One platform, many programs.
Immune-Tag Conjugate for HER2+ bladder cancer (TCC) and head-and-neck squamous cell carcinoma (HNSCC).
Initial in vivo POC complete. Definitive comparator study underway.
We didn't pick an indication and hoped the immunology would work. We picked the indications where the immunology was already in place, and gave it a target.
BCG is standard-of-care in non-muscle-invasive bladder cancer. CMV memory is present in over 90% of adults. ORION redirects immunity already in the patient.
Both tumors drop HER2 under T-DXd. Epitope spreading keeps ORION working after the marker is gone.
Both indications routinely use intra-tumoral or local delivery. Local activation drives systemic response.